Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity
Open Access
- 27 February 2015
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Communications
- Vol. 6 (1), 6169
- https://doi.org/10.1038/ncomms7169
Abstract
Predicting clinical response to anticancer drugs remains a major challenge in cancer treatment. Emerging reports indicate that the tumour microenvironment and heterogeneity can limit the predictive power of current biomarker-guided strategies for chemotherapy. Here we report the engineering of personalized tumour ecosystems that contextually conserve the tumour heterogeneity, and phenocopy the tumour microenvironment using tumour explants maintained in defined tumour grade-matched matrix support and autologous patient serum. The functional response of tumour ecosystems, engineered from 109 patients, to anticancer drugs, together with the corresponding clinical outcomes, is used to train a machine learning algorithm; the learned model is then applied to predict the clinical response in an independent validation group of 55 patients, where we achieve 100% sensitivity in predictions while keeping specificity in a desired high range. The tumour ecosystem and algorithm, together termed the CANScript technology, can emerge as a powerful platform for enabling personalized medicine.Keywords
This publication has 70 references indexed in Scilit:
- Opposing Effect of EGFRWT on EGFRvIII-Mediated NF-κB Activation with RIP1 as a Cell Death SwitchCell Reports, 2013
- Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancerNature, 2012
- Imaging Tumor-Stroma Interactions during Chemotherapy Reveals Contributions of the Microenvironment to ResistanceCancer Cell, 2012
- Paracrine and Autocrine Signals Induce and Maintain Mesenchymal and Stem Cell States in the BreastCell, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Phosphoproteomic Analysis of Signaling Pathways in Head and Neck Squamous Cell Carcinoma Patient SamplesThe American Journal of Pathology, 2011
- Lung Cancer Serum Biomarker Discovery Using Glycoprotein Capture and Liquid Chromatography Mass SpectrometryJournal of Proteome Research, 2010
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell SubpopulationsCell, 2010
- An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer CellsCancer Cell, 2010
- Modelling tissues in 3D: the next future of pharmaco-toxicology and food research?Genes & Nutrition, 2008